MRNA PE Ratio & Valuation,Is MRNA Overvalued

MRNA Relative Valuation

MRNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MRNA is overvalued; if below, it's undervalued.

Historical Valuation

Moderna Inc (MRNA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.01 is considered Undervalued compared with the five-year average of -1.64. The fair price of Moderna Inc (MRNA) is between 231.03 to 252.42 according to relative valuation methord. Compared to the current price of 29.28 USD , Moderna Inc is Undervalued By 87.33%.

Relative Value

Fair Zone

231.03-252.42

Current Price：29.28

87.33%

Undervalued

-3.51

-2.18

EV/EBITDA

Moderna Inc. (MRNA) has a current EV/EBITDA of -2.18. The 5-year average EV/EBITDA is -1.94. The thresholds are as follows: Strongly Undervalued below -21.40, Undervalued between -21.40 and -11.67, Fairly Valued between 7.80 and -11.67, Overvalued between 7.80 and 17.53, and Strongly Overvalued above 17.53. The current Forward EV/EBITDA of -2.18 falls within the Historic Trend Line -Fairly Valued range.

-1.65

EV/EBIT

Moderna Inc. (MRNA) has a current EV/EBIT of -1.65. The 5-year average EV/EBIT is -0.92. The thresholds are as follows: Strongly Undervalued below -17.97, Undervalued between -17.97 and -9.44, Fairly Valued between 7.61 and -9.44, Overvalued between 7.61 and 16.14, and Strongly Overvalued above 16.14. The current Forward EV/EBIT of -1.65 falls within the Historic Trend Line -Fairly Valued range.

6.01

Moderna Inc. (MRNA) has a current PS of 6.01. The 5-year average PS is 6.22. The thresholds are as follows: Strongly Undervalued below 0.73, Undervalued between 0.73 and 3.47, Fairly Valued between 8.96 and 3.47, Overvalued between 8.96 and 11.70, and Strongly Overvalued above 11.70. The current Forward PS of 6.01 falls within the Historic Trend Line -Fairly Valued range.

-4.79

P/OCF

Moderna Inc. (MRNA) has a current P/OCF of -4.79. The 5-year average P/OCF is -3.59. The thresholds are as follows: Strongly Undervalued below -32.14, Undervalued between -32.14 and -17.86, Fairly Valued between 10.68 and -17.86, Overvalued between 10.68 and 24.96, and Strongly Overvalued above 24.96. The current Forward P/OCF of -4.79 falls within the Historic Trend Line -Fairly Valued range.

-4.37

P/FCF

Moderna Inc. (MRNA) has a current P/FCF of -4.37. The 5-year average P/FCF is -2.33. The thresholds are as follows: Strongly Undervalued below -32.03, Undervalued between -32.03 and -17.18, Fairly Valued between 12.52 and -17.18, Overvalued between 12.52 and 27.37, and Strongly Overvalued above 27.37. The current Forward P/FCF of -4.37 falls within the Historic Trend Line -Fairly Valued range.

Moderna Inc (MRNA) has a current Price-to-Book (P/B) ratio of 1.24. Compared to its 3-year average P/B ratio of 2.26 , the current P/B ratio is approximately -45.40% higher. Relative to its 5-year average P/B ratio of 6.00, the current P/B ratio is about -79.42% higher. Moderna Inc (MRNA) has a Forward Free Cash Flow (FCF) yield of approximately -23.05%. Compared to its 3-year average FCF yield of -14.47%, the current FCF yield is approximately 59.23% lower. Relative to its 5-year average FCF yield of -3.86% , the current FCF yield is about 497.44% lower.

1.24

P/B

Median3y

2.26

Median5y

6.00

-23.05

FCF Yield

Median3y

-14.47

Median5y

-3.86

Competitors Valuation Multiple

The average P/S ratio for MRNA's competitors is 194.02, providing a benchmark for relative valuation. Moderna Inc Corp (MRNA) exhibits a P/S ratio of 6.01, which is -96.9% above the industry average. Given its robust revenue growth of -45.44%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of MRNA decreased by 29.15% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.12 to -3.66.

The secondary factor is the Revenue Growth, contributed -45.44%to the performance.

Overall, the performance of MRNA in the past 1 year is driven by P/E Change. Which is more unsustainable.

-45.44%

1.86B → 1.02B

Revenue Growth

-2912.86%

0.70 → -19.69

Margin Expansion

2929.15%

-0.12 → -3.66

P/E Change

-29.15%

41.58 → 29.46

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Moderna Inc (MRNA) currently overvalued or undervalued?

What is Moderna Inc (MRNA) fair value?

MRNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Moderna Inc (MRNA) is between 231.03 to 252.42 according to relative valuation methord.

How does MRNA's valuation metrics compare to the industry average?

The average P/S ratio for MRNA's competitors is 194.02, providing a benchmark for relative valuation. Moderna Inc Corp (MRNA) exhibits a P/S ratio of 6.01, which is -96.90% above the industry average. Given its robust revenue growth of -45.44%, this premium appears unsustainable.

What is the current P/B ratio for Moderna Inc (MRNA) as of Dec 15 2025?

As of Dec 15 2025, Moderna Inc (MRNA) has a P/B ratio of 1.24. This indicates that the market values MRNA at 1.24 times its book value.

What is the current FCF Yield for Moderna Inc (MRNA) as of Dec 15 2025?

As of Dec 15 2025, Moderna Inc (MRNA) has a FCF Yield of -23.05%. This means that for every dollar of Moderna Inc’s market capitalization, the company generates -23.05 cents in free cash flow.

What is the current Forward P/E ratio for Moderna Inc (MRNA) as of Dec 15 2025?

As of Dec 15 2025, Moderna Inc (MRNA) has a Forward P/E ratio of -3.51. This means the market is willing to pay $-3.51 for every dollar of Moderna Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Moderna Inc (MRNA) as of Dec 15 2025?

As of Dec 15 2025, Moderna Inc (MRNA) has a Forward P/S ratio of 6.01. This means the market is valuing MRNA at $6.01 for every dollar of expected revenue over the next 12 months.

MRNA Valuation